Advertisement

Uncategorized

In a recent BMJ article, investigators uncovered more than 25 percent of FDA cancer and hematology drug reviewers who left the agency between 2001 and 2010 now work or consult for pharmaceutical companies, according to Kaiser Health News. In the…

Advertisement
Advertisement